On 2015 May 25, Tove Alm commented:
Response to letter by Islam
Shahidul Islam refers to our research article in Science “Tissue-based map of the human proteome” (M. Uhlén et al 23 January, 2015, p. 394) and claims that “they have skipped the control experiments because that would slow down the productivity”. This is of course not true; a large portion of the resources for the project are invested in validation of the antibodies.
A considerable amount of the resources in the program have been used to perform control experiments for the antibodies displayed in the portal and a lot of effort has been put into the visualization of the primary data to allow the scientific community to explore the data behind the control experiments. At present, more than 60,000 antibodies have been validated using Western blots and high-density micro arrays and these efforts have been published in hundreds of articles from our group (www.proteinatlas.org/about/publications). The result in each application is also compared to RNA expression levels and what is known in literature. In addition, to further examine the antibodies, a pipeline for validation of antibody specificity using gene silencing has been established. The results are currently available for a subset of the antibodies in the Protein Atlas.
The open-source policy applied to all antibodies published on the Atlas allows transparency and users may themselves review the experiments supporting the specificity of a particular antibody through the “Antibody/antigen” page (see example: www.proteinatlas.org/ENSG00000141510-TP53/antibody).
The statement by Islam that the antibodies are available through Atlas Antibodies and therefore “reduces the reliability of the immunohistochemistry images” is also difficult to understand. The Human Protein Atlas includes antibodies from more than 40 commercial providers and all primary data supporting the respective antibody is shown as an open resource on the antibody/antigen page for each antibody (see example link above). In the Human Protein Atlas program, a requirement for including an antibody has from the start been that the corresponding antibody must be available to the scientific community through a commercial provider. This is important, since it allows for the use of the same antibody by all researchers interested in human biology and medicine.
As far as we know, there are no past or current efforts with a more comprehensive pipe-line of systematic antibody validations.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.